Circulating miR-106a in serum are potential biomarker for renal cell carcinoma
10.3760/cma.j.issn.1000-6702.2015.11.
- VernacularTitle:肾透明细胞癌患者血清中微小RNA-106a的表达及临床意义
- Author:
Jin GUAN
;
Tusong HAMULATI
;
Yujie WANG
;
Wenguang WANG
;
Azhati BAIHETIYA
;
Rexiati MULATI
- Publication Type:Journal Article
- Keywords:
Circulating microRNA;
miR-106a;
Renal cell carcinoma;
Molecular markers
- From:
Chinese Journal of Urology
2015;36(12):891-894
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the circulating miR-106a levels in serum before and after surgery in patients with renal clear cell carcinoma,and to explore its relationship with clinical-pathological parameters.Methods 30 serum samples from patients with renal clear cell carcinoma were collected before and after surgery during February 2013 to July 2014.This study included 30 normal controls.All serum miR-106a levels were detected using the real-time PCR.Results The serum miR-l06a levels in patients with renal clear cell carcinoma pre-operatively wcre significantly greater than normal controls (Z =-4.251,P =0.0001).The serum miR-106a levels in patients post-operatively had no significant differences compared to normal controls (Z =-0.244,P =0.807).The serum miR-106a levels in post-operative samples were significantly lower than the pre-operative samples (Z =-4.229,P =0.0001).Serum miR-106a levels and other clinical-pathological parameters had no correlation in patients with renal clear cell carcinoma(tumor size:Z =-0.775,P =0.439;Fuhrman grade:Z =-1.694,P =0.090).The receiver operating characteristic curve was used to distinguish pre-operative samples and normal controls,its AUC was 0.819 (95％ CI:0.710-0.929,P =0.0001) with 86.7％ sensitivity and 70.0％ specificity.Conclusions The serum miR-106a levels in patients with renal clear cell carcinoma pre-operatively were significantly greater than post-operatively with no correlation in tumor size and Fuhrman grade.The outcome suggested that serum miR-106a can be regarded as a potential molecular marker in renal clear cell carcinoma.
